Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Handler

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Acta Neuropathologica|November 19, 2013
Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymomaLindsey M Hoffman, Andrew M Donson, Ichiro Nakachi, et al.
Eneuro|April 17, 2025
Characterizing the Diversity of Layer 2/3 Human Neocortical Neurons in Pediatric EpilepsyJ Keenan Kushner, Paige B Hoffman, Christine R Brzezinski, et al.
Molecular Cancer Therapeutics|June 22, 2018
Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood EpendymomaAndrew M Donson, Vladimir Amani, Elliot A Warner, et al.
Pediatric Blood & Cancer|January 20, 2018
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapyDavis A Witt, Andrew M Donson, Vladimir Amani, et al.
Cancer Immunology Research|May 14, 2015
Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A EpendymomaAndrea M Griesinger, Rebecca J Josephson, Andrew M Donson, et al.
Cell Reports|August 14, 2020
Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and EtiologyAustin E Gillen, Kent A Riemondy, Vladimir Amani, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
Pediatric Blood & Cancer|November 6, 2024
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531Julie Voeller, Howard M Katzenstein, Arlene Naranjo, et al.
Oncotarget|July 25, 2016
Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastomaEric W Prince, Ilango Balakrishnan, Monil Shah, et al.
Epilepsia|January 7, 2012
A proteomic analysis of pediatric seizure cases associated with astrocytic inclusionsNaomi P Visanji, Janice C Wong, Simon X Wang, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Acta Neuropathologica|November 19, 2013
Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymomaLindsey M Hoffman, Andrew M Donson, Ichiro Nakachi, et al.
Eneuro|April 17, 2025
Characterizing the Diversity of Layer 2/3 Human Neocortical Neurons in Pediatric EpilepsyJ Keenan Kushner, Paige B Hoffman, Christine R Brzezinski, et al.
Molecular Cancer Therapeutics|June 22, 2018
Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood EpendymomaAndrew M Donson, Vladimir Amani, Elliot A Warner, et al.
Pediatric Blood & Cancer|January 20, 2018
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapyDavis A Witt, Andrew M Donson, Vladimir Amani, et al.
Cancer Immunology Research|May 14, 2015
Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A EpendymomaAndrea M Griesinger, Rebecca J Josephson, Andrew M Donson, et al.
Cell Reports|August 14, 2020
Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and EtiologyAustin E Gillen, Kent A Riemondy, Vladimir Amani, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
Pediatric Blood & Cancer|November 6, 2024
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531Julie Voeller, Howard M Katzenstein, Arlene Naranjo, et al.
Oncotarget|July 25, 2016
Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastomaEric W Prince, Ilango Balakrishnan, Monil Shah, et al.
Epilepsia|January 7, 2012
A proteomic analysis of pediatric seizure cases associated with astrocytic inclusionsNaomi P Visanji, Janice C Wong, Simon X Wang, et al.
Pageof 9